Quinlan Paul T. - 30 Jun 2023 Form 4 Insider Report for CymaBay Therapeutics, Inc.

Role
General Counsel
Signature
/s/ Paul Quinlan
Issuer symbol
N/A
Transactions as of
30 Jun 2023
Net transactions value
-$35,550
Form type
4
Filing time
30 Jun 2023, 16:51:25 UTC
Previous filing
17 May 2023
Next filing
14 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CBAY Common Stock Options Exercise $14,700 +5,000 $2.94* 5,000 30 Jun 2023 Direct
transaction CBAY Common Stock Sale $50,250 -5,000 -100% $10.05 0 30 Jun 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CBAY Employee Stock Option (right to buy) Options Exercise $0 -5,000 -2.6% $0.000000 190,000 30 Jun 2023 Common Stock 5,000 $2.94 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan entered into on February 14, 2023.
F2 The option grant vests as to 1/48 of the underlying shares monthly from January 1, 2022.